Mechanisms of Viral Oncogenesis — Questions

• E6 degrades p53: E6 recruits the cellular ubiquitin ligase E6AP to target p53 for proteasomal degradation, removing p53-dependent apoptosis and cell-cycle arrest.
• E7 inactivates Rb: E7 binds the retinoblastoma protein (Rb) and displaces it from the E2F transcription factors.
• E2F released: free E2F transcribes the S-phase genes, so the cell is driven into DNA synthesis.
• G1/S checkpoint overridden: the combined action pushes the cell across the G1/S restriction point without normal checkpoint control.
• Loss of both the Rb and p53 brakes together produces unchecked proliferation and the genomic instability that underlies transformation.

A complete answer follows the sequence from infection through persistence and integration to the loss of both tumour-suppressor brakes, and notes that the virus is necessary but not sufficient.

Infection and productive cycle

The virus reaches the basal keratinocytes through a microabrasion in the epithelium and establishes its genome as an episome. In a productive infection the viral life cycle is tied to keratinocyte differentiation, and most such infections are transient and cleared by cell-mediated immunity.

Persistence and integration

Transformation is the exception and requires a persistent infection with a high-risk type, chiefly HPV16 and HPV18. Progression is associated with integration of the viral genome into the host chromosome, which disrupts the E2 gene. Because E2 represses the viral oncogenes, its loss lets E6 and E7 be expressed without restraint.

Deregulated oncoprotein expression

E6 recruits the ubiquitin ligase E6AP to degrade p53, removing the apoptosis and arrest response, while E7 inactivates the retinoblastoma protein (Rb), releasing E2F and forcing the cell into S phase. The combined loss of both tumour suppressors drives continuous proliferation, genomic instability, and activation of telomerase.

Progression to cancer

These changes accumulate over years as the epithelium passes through progressively higher-grade intraepithelial neoplasia (CIN) to invasive carcinoma. Cofactors including persistence, immunosuppression (notably HIV co-infection) and smoking raise the risk, and only a small fraction of infected women develop cancer, which is why HPV is necessary but not sufficient.

Infectious agents account for roughly 13% of cancers worldwide, about 2.2 million new cases a year. Oncogenic viruses make up the majority of that figure, with the bacterium Helicobacter pylori contributing most of the remainder.

The share is higher in low- and middle-income countries, where most virus-attributable cancers arise.

HPV18 integrates more readily and is over-represented in cervical adenocarcinoma, whereas HPV16 is more replicative and dominates squamous cancers.

Genital warts are caused by low-risk types such as 6 and 11.

EBV-positive gastric cancer is a distinct subtype with amplification of the PD-L1 immune-checkpoint ligand (and JAK2), against a largely wild-type p53 background, marking the virus as a driver.

Ultraviolet and aflatoxin signatures and BCR-ABL belong to other cancers.

In the equatorial African belt, holoendemic Plasmodium falciparum malaria drives B-cell proliferation and weakens EBV-specific immunity, raising the chance of the c-myc translocation that defines Burkitt lymphoma.

Aflatoxin, ultraviolet light, tobacco and alcohol are cofactors for other cancers.

LMP1 behaves as a constitutively active CD40 receptor, signalling without ligand to drive nuclear factor kappa B (NF-kB) and JAK-STAT survival pathways.

LMP2A mimics the B-cell receptor and EBNA2 mimics Notch.

Integration commonly disrupts the viral E2 gene, and because E2 represses E6 and E7, its loss lets these oncoproteins be expressed without restraint.

HPV carries no captured host oncogene, and the cancer cells produce no virus.

The L1 capsid protein self-assembles into virus-like particles that elicit neutralising antibodies, preventing infection.

The vaccine is prophylactic, not therapeutic: it neither cures established infection, clears integrated DNA, nor kills tumour cells.

E7 binds and degrades the retinoblastoma protein (Rb), releasing the E2F transcription factors and forcing the cell into S phase.

p53 is the target of E6, not E7; the others are not the transforming target of E7.

HTLV-1, the human tumour retrovirus, causes adult T-cell leukaemia/lymphoma after a latency of decades in a small fraction of carriers.

The other malignancies are driven by different viruses.

Restoring immunity is decisive: antiretroviral therapy is started immediately, whatever the CD4 count, and often causes regression, with liposomal doxorubicin reserved for advanced disease.

Splenectomy, rituximab monotherapy and aciclovir have no role, and withholding treatment worsens outcomes.

Integration selects a truncated large T that keeps the Rb-binding region but loses the replication function, so the virus drives proliferation precisely because it can no longer complete its life cycle.

The antigen is retained in the tumour cells, not absent, secreted, or fused to MYCL.

KSHV is present in essentially every Kaposi sarcoma lesion and is its necessary cause. The lesions behave as a virus-driven angioproliferative process rather than a classic monoclonal tumour.

The lower proportions understate what is effectively a complete association.

Nasopharyngeal carcinoma is over 95% Epstein-Barr virus (EBV)-positive, and it clusters in East and Southeast Asia against host genetic and dietary cofactors.

The other viruses drive different tumours and are not found in nasopharyngeal carcinoma.

A virus supplies only some of the steps to malignancy; host mutations and cofactors accumulated over time supply the rest, so the virus is necessary but not sufficient.

The long latency and low penetrance exclude a purely inherited, single-step, or virus-independent process.

Infant hepatitis B vaccination reduces hepatocellular carcinoma, the first demonstration that a vaccine can prevent a human cancer and strong proof of the causal link.

It is a prophylactic subunit vaccine, not therapeutic, live, mRNA, or active against hepatitis C.

All Burkitt lymphomas carry a translocation, classically t(8;14), that places c-myc under an immunoglobulin promoter. EBV contributes by blocking the apoptosis that Myc overexpression would otherwise trigger.

BCR-ABL, BCL2 translocation, EGFR amplification and TERT-promoter mutations define other tumours.

HTLV-1 spreads by cell-to-cell contact, and breastfeeding is the principal route of mother-to-child transmission; avoiding it reduces vertical spread.

Sexual and parenteral routes transmit between adults but are not the main vertical route.

Direct-acting antivirals cure over 98% of infections, and cure measurably lowers the subsequent risk of hepatocellular carcinoma, the cleanest demonstration that removing a virus prevents cancer.

There is no licensed hepatitis C vaccine, and the other options do not by themselves establish causation.

Essentially every cervical cancer carries high-risk HPV, making it the strongest virus-cancer association known.

The lower figures understate a relationship that is, for practical purposes, complete.

Integration drives insertional activation of cell-cycle and immortalisation genes and yields a truncated HBx protein, a direct route that can cause cancer without the cirrhotic background the inflammatory route needs.

Inflammation, high viral load, hepatitis D co-infection and aflatoxin all raise risk but act through the cirrhotic pathway.

In direct oncogenesis the viral genome is present in essentially all tumour cells, and a continuously expressed oncoprotein maintains transformation.

Chronic inflammation and a dependence on immunosuppression describe the indirect routes.

E6 recruits the cellular ubiquitin ligase E6AP to degrade p53, removing the apoptosis and arrest response.

E7 targets the retinoblastoma protein, E5 hyperactivates the epidermal growth factor receptor, L1 is the capsid protein, and E2 represses E6 and E7.

HBZ, encoded on the antisense 3’ long terminal repeat, is expressed continuously and is the one viral protein always present in leukaemic cells.

Tax initiates transformation but is often silenced later; Env, Gag and Rex are structural or regulatory proteins, not clonal maintainers.

Human immunodeficiency virus carries no oncogene and transforms no cell itself. It raises cancer risk only indirectly, by depleting CD4 T cells and removing the immune surveillance that holds the other oncogenic viruses in check.

The other four are direct carcinogens that express viral oncoproteins within the tumour cell: HPV (E6 and E7), Epstein-Barr virus (LMP1 and EBNA), Merkel cell polyomavirus (truncated large T) and Kaposi sarcoma-associated herpesvirus (its pirated cell-cycle and survival genes).

Hepatitis C has no DNA stage, does not integrate, and encodes no oncogene, and its proteins are not found in all tumour cells; it causes liver cancer through decades of inflammation and cirrhosis.

HPV, HBV, EBV and Merkel cell polyomavirus all express oncoproteins or integrate.

Human papillomavirus causes roughly half of all virus-attributable cancers, driven above all by cervical cancer.

Hepatitis B is second, then hepatitis C and Epstein-Barr virus; KSHV and HTLV-1 together account for only a small share.

Tax is highly immunogenic, so cytotoxic T cells select against cells that express it. Silencing the 5’ long terminal repeat shuts Tax off and lets the infected cell persist, while HBZ on the 3’ repeat continues.

Silencing lowers rather than raises virion production and is unrelated to integration or a lytic cycle.

A complete answer groups the strategies rather than listing viruses, and ends with the point that a virus is necessary but not sufficient.

Inactivating the tumour-suppressor pathways

The direct DNA tumour viruses force a resting cell into S phase by disabling the two master tumour suppressors together: the retinoblastoma protein (Rb), which restrains cell-cycle entry, and p53, which triggers arrest or apoptosis in response to inappropriate proliferation. High-risk HPV does this with E7 against Rb and E6 against p53; the polyomavirus large T antigen engages both; adenovirus E1A and E1B define the paradigm.

Driving constitutive proliferative and survival signalling

Rather than degrade tumour suppressors, the herpesviral and retroviral oncoproteins mimic the cell’s own growth signals: Epstein-Barr virus LMP1 acts as a ligand-independent CD40 receptor driving survival signalling, KSHV deploys pirated cytokine and cell-cycle genes, and HTLV-1 Tax switches on host proliferation pathways.

Insertional mutagenesis

The retroviruses integrate a DNA copy of their genome into the host chromosome. Each integration is in effect a mutation, and a provirus landing beside a host proto-oncogene can activate it, producing a clonal tumour.

Indirect mechanisms

Where no oncoprotein is supplied, transformation proceeds through chronic inflammation and regeneration, which accumulate host mutations (hepatitis B and C), or through loss of immune surveillance over latently infected cells.

Necessary but not sufficient

In every case the virus supplies only some of the steps to malignancy; host mutations and cofactors are also required, which is why cancer is clonal, late, and develops in only a small fraction of those infected.

A complete answer explains the surveillance mechanism, names the virus-tumour pairs, and notes the effect of restoring immunity.

Loss of surveillance. The latent oncogenic viruses persist for life in most adults but are normally held in check by T-cell surveillance, which removes infected and transformed cells. When that surveillance fails, in advanced HIV infection, after transplant immunosuppression, or in primary immunodeficiency, the latently infected cells proliferate unchecked and the associated cancers emerge.

The virus-tumour pairs. The characteristic pairings are Kaposi sarcoma-associated herpesvirus with Kaposi sarcoma and primary effusion lymphoma; Epstein-Barr virus with the B-cell lymphomas, including post-transplant lymphoproliferative disorder and the central nervous system lymphoma of advanced HIV; and high-risk human papillomavirus with cervical and other anogenital cancers, which are more common and more aggressive in women living with HIV.

HIV’s role and the effect of treatment. HIV itself encodes no oncogene and transforms no cell; its entire oncogenic contribution is the depletion of CD4 T cells and the resulting loss of control over the other viruses. Restoring immune function with antiretroviral therapy reduces the incidence of these cancers, though it does not abolish it.

A complete answer names the seven recognised tumour viruses, pairs each with its principal cancer, and applies the direct or indirect distinction consistently.

Human immunodeficiency virus is the eighth recognised carcinogen but is not a tumour virus: it encodes no oncogene and raises cancer risk only indirectly, through the immunosuppression that unmasks the viruses above. A direct carcinogen expresses an oncoprotein within the tumour cell, with the viral genome present in essentially all tumour cells; an indirect carcinogen promotes cancer through chronic inflammation or loss of immune surveillance.